Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Nancy Thornberry

Chief Executive Officer

Kallyope

Nancy has been Chief Executive Officer of Kallyope Inc., a biotech company focused on the therapeutic potential of the gut-brain axis, since the company’s launch in November 2015. She was formerly Senior Vice President and Franchise Head, Diabetes and Endocrinology, Merck & Co. Inc. In this role she led discovery and clinical research in diabetes, osteoporosis, fertility, and contraception. Prior to her role as Franchise Head, Nancy initiated and was a leader of Merck’s dipeptidyl peptidase 4 (DPP-4) project, which resulted in the discovery of JANUVIA® for the treatment of Type 2 diabetes. Among other notable scientific accomplishments is the identification of the first caspase, interleukin-1β converting enzyme (ICE/caspase-1). For her scientific contributions she has received numerous awards, including the Merck Presidential Fellowship, Merck Directors Award, Heroes of Chemistry Award by the American Chemical Society, and in 2011 received the Pharmaceuticals Research and Manufacturers of America (PhRMA) Discoverers Award, which honors research scientists whose work has been of special benefit to humankind. In addition to her role at Kallyope, she serves as a Director at Intarcia Therapeutics and Abide Therapeutics and is a member of the Life Sciences Advisory Council for the New York City Economic Development Corporation (NYEDC).

This speaker's sessions:

Back